Classic Kaposi Sarcoma Clinical Trial
Official title:
A Phase 2 Study of Nivolumab Plus Ipilimumab in Previously Treated Classical Kaposi Sarcoma (CKS)
A Phase 2 study of nivolumab plus ipilimumab in previously treated classical Kaposi Sarcoma (CKS)
A prospective, single arm, interventional study. All patients will receive IV nivolumab 3mg/kg every two weeks and ipilimumab 1mg/kg every 6 weeks. Patients will be treated until disease progression or intolerable toxicity for a maximal period of two years, with an option to re-initiate therapy upon progression in patients with prior documented response to investigational therapy (unless treatment was held for progression of disease). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00521092 -
Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT05846724 -
Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma
|
Phase 2 |